Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00826241 · ClinicalTrials.gov registry record · Phase 2
Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma
A Phase 2 study, sponsored by National Institutes of Health Clinical Center (CC).
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT00826241 is a Phase 2 study that has completed, run by National Institutes of Health Clinical Center (CC). The registered enrollment target is 58 participants.
The verdict
NCT00826241, a Phase 2 study, has completed, sponsored by National Institutes of Health Clinical Center (CC).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if lapatinib when given in combination with temozolomide can help to control ependymoma that has come back after treatment. The safety of this combination will also be studied.
Interventions
- DRUG Temozolomide
- DRUG Lapatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2009-01 |
| Est. Completion | 2018-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00826241
The ClinicalTrials.gov registry entry for NCT00826241 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institutes of Health Clinical Center (CC), which has 338 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Temozolomide is the first listed.
NCT00826241 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00826241 about?
NCT00826241 is a clinical study titled "Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma". The goal of this clinical research study is to learn if lapatinib when given in combination with temozolomide can help to control ependymoma that has come back after treatment. The safety of this combination will also be studied.
What is the current status of trial NCT00826241?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2009-01. Estimated completion is 2018-07-31.
What interventions are being tested in trial NCT00826241?
The interventions under investigation include: Temozolomide (DRUG), Lapatinib (DRUG).
Who is sponsoring clinical trial NCT00826241?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.